Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure
Andy C. Rawstron(St James's University Hospital), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Andrew R. Pettitt(University of Liverpool), Ruth M. de Tute(St James's University Hospital), Francesca Yates(Cancer Research UK Clinical Trials Unit), Talha Munir(Leeds Teaching Hospitals NHS Trust), Kristian Brock(Cancer Research UK Clinical Trials Unit), Adrian Bloor(The Christie NHS Foundation Trust), Sophie Cramp(Cancer Research UK Clinical Trials Unit), Oonagh Sheehy(University of Leeds), Chris Fegan(Cardiff and Vale University Health Board), Samuel Munoz Vicente(Cancer Research UK Clinical Trials Unit), Nichola Webster(University of Leeds), Christopher P. Fox(Nottingham University Hospitals NHS Trust), Stephen Devereux, Surita Dalal(University of Leeds), Rebecca Bishop(Cancer Research UK Clinical Trials Unit), Donald Macdonald(Imperial College Healthcare NHS Trust)
Cited by 7
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k